We have collected information about Antibody Delivery Sirna for you. Follow the links to find out details on Antibody Delivery Sirna.
https://academic.oup.com/nar/article/43/2/1189/2414709
Dec 30, 2014 · Delivery of siRNA is a key hurdle to realizing the therapeutic promise of RNAi. By targeting internalizing cell surface antigens, antibody–siRNA complexes provide a possible solution. However, initial reports of antibody–siRNA complexes relied on non-specific charged interactions and have not been broadly applicable.Author: Trinna L. Cuellar, Dwight Barnes, Christopher Nelson, Joshua Tanguay, Shang-Fan Yu, Xiaohui Wen, Suz...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333408/
Jan 30, 2015 · Delivery of siRNA is a key hurdle to realizing the therapeutic promise of RNAi. By targeting internalizing cell surface antigens, antibody–siRNA complexes provide a possible solution. However, initial reports of antibody–siRNA complexes relied on non-specific charged interactions and have not been broadly applicable.Author: Trinna L. Cuellar, Dwight Barnes, Christopher Nelson, Joshua Tanguay, Shang-Fan Yu, Xiaohui Wen, Suz...
http://www.nature.com/articles/nbt1101
May 22, 2005 · Delivery of small interfering RNAs (siRNAs) into cells is a key obstacle to their therapeutic application. We designed a protamine-antibody fusion protein to deliver siRNA to HIV-infected or ...Author: Erwei Song, Pengcheng Zhu, Sang Kyung Lee, Dipanjan Chowdhury, Steven Kussman, Derek M Dykxhoorn, Yi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2977003/
Jun 11, 2010 · Conjugation or complexation of siRNA to antibody increases the specificity of siRNA delivery and minimize the off-target effects. Fusion of protamine to the C terminus of the heavy chain Fab fragment (F105) against HIV-1 envelope yielded the fusion protein F105-P that binds FITC-labeled siRNA in a 1:6 molar ratio.Author: Jie Wang, Ze Lu, M. Guillaume Wientjes, Jessie L.-S. Au
https://www.hindawi.com/journals/jdd/2017/6971297/
Over the past 20 years, a diverse group of ligands targeting surface biomarkers or receptors has been identified with several investigated to target siRNA to tumors. Many approaches to developing tumor-homing peptides, RNA and DNA aptamers, and single-chain variable fragment antibodies by using phage display, in vitro evolution, and recombinant antibody methods could not have been imagined by ...Author: Qixin Leng, Martin C. Woodle, A. James Mixson
https://clincancerres.aacrjournals.org/content/21/6/1383
Mar 15, 2015 · Translational Relevance. Anti-EGFR antibody therapy is successful in multiple cancers. Patients with colon cancer harboring KRAS mutations do not benefit from anti-EGFR antibody therapy. This article demonstrates that an anti-EGFR antibody–siRNA complex can partly overcome this resistance of adenocarcinoma cell lines, including colon cancer cells, in vitro and in vivo.Author: Sebastian Bäumer, Nicole Bäumer, Neele Appel, Lisa Terheyden, Julia Fremerey, Sonja Schelhaas, Eva W...
Searching for Antibody Delivery Sirna?
You can just click the links above. The data is collected for you.
